Idec Pharmaceuticals Corporation

Other

Biogen Idec, Inc.

Cheryl Janne Heard

Peter Brams

Roland A Newman

Edward E Walsh

Soulaima Salim Chamat

Li-Zhen Pan

Nabil Hanna

Darrell R Anderson

William S Shestowsky

The present invention relates to the identification of macaque antibodies to human B7.1 and B7.2 by screening of phage display libraries or monkey heterohybridomas obtained using B lymphocytes from B7.1 and/or B7.2 immunized monkeys. More specifically, the invention provides four monkey monoclonal antibodies 7B6, 16C10, 7C10 and 20C9 which inhibit the B7:CD28 pathway and thereby function as effective immunosuppressants. The invention further provides the complete DNA and amino acid sequences of the light and heavy chain of three PRIMATIZED&#xae; antibodies derived from those monkey monoclonal antibodies which bind B7.1 and possibly B7.2, PRIMATIZED&#xae; 7C10, PRIMATIZED&#xae; 7B6 and PRIMATIZED&#xae; 16C10. These PRIMATIZED&#xae; and monkey antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.

Anti-CD80 antibodies

The present invention relates to methods for treating B cell lymphoma using CD80-specific antibodies.

Methods for treating b cell lymphoma using CD80-specific antibodies

The present invention relates to the identification of macaque antibodies to human B7.1 and B7.2 by screening of phage display libraries or monkey heterohybridomas obtained using B lymphocytes from B7.1 and/or B7.2 immunized monkeys. More specifically, the invention provides four monkey monoclonal antibodies 7B6, 16C10, 7C10 and 20C9 which inhibit the B7:CD28 pathway and thereby function as effective immunosuppressants. The invention further provides the complete DNA and amino acid sequences of the light and heavy chain of three primatized antibodies derived from those monkey monoclonal antibodies which bind B7.1 and possibly B7.2, primatized 7C10, primatized 7B6 and primatized 16C10. These primatized and monkey antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.

Treatment of psoriasis using anti-B7.1 (CD80) antibodies

Human B7.1-specific primatized antibodies and transfectomas expressing

Novel human monoclonal antibodies, and their corresponding nucleic acid sequences having high affinity for the human RSV-F protein are provided.

Neutralizing high affinity human monoclonal antibodies specific to RSV

A method of detecting RSV (Respiratory Syncytial Virus) in an analyte using high affinity human monoclonal antibodies is provided.

A method of obtaining high affinity human monoclonal antibodies having a Kd of .ltoreq.2.times.10.sup.-9 molar in SCID mice is provided.

A method of treating or preventing RSV infection by the administration of high affinity human monoclonal antibodies having a Kd of about 2.times.10.sup.-9 to 10.sup.-10 molar is provided.

A highly efficient method for generating human antibodies in particular which are specific to be RSV fusion protein which combines in vitro priming of human spleen cells and antigen boosting in SCID mice is taught. This method provides for very high human antibody titers which are predominantly of the IgG isotype which contain antibodies of high specificity and affinity to desired antigens. This method is well suited for generating human monoclonal antibodies for therapeutic and diagnostic applications as well as for rescue of human cells for generation of combinational human antibody gene libraries. Two human monoclonal antibodies, RF-1 and RF-2 which each possess an affinity for RSV F-protein about 2.times.10.sup.-9 to 10.sup.-10 Molar are taught as well as their corresponding amino acid and DNA sequences. These antibodies are to be used therapeutically and prophylactically for treating or preventing RSV infection, as well as for diagnosis of RSV in analytes.

Growing community of inventors

Encinitas, CA, United States of America

Cheryl Janne Heard